Arrowhead Pharmaceuticals (ARWR) Projected to Post Earnings on Thursday

Arrowhead Pharmaceuticals (NASDAQ:ARWR) is expected to be releasing its Q1 2026 results after the market closes on Thursday, February 5th. Analysts expect the company to announce earnings of $0.82 per share and revenue of $225.6580 million for the quarter. Parties can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Thursday, February 5, 2026 at 4:30 PM ET.

Arrowhead Pharmaceuticals Stock Up 5.3%

Shares of NASDAQ ARWR opened at $73.00 on Tuesday. The firm’s 50-day moving average is $65.78 and its two-hundred day moving average is $42.37. The company has a market capitalization of $10.22 billion, a PE ratio of -912.39 and a beta of 1.21. Arrowhead Pharmaceuticals has a 12-month low of $9.57 and a 12-month high of $76.76. The company has a debt-to-equity ratio of 0.43, a current ratio of 4.86 and a quick ratio of 4.86.

Insider Buying and Selling

In other news, insider James C. Hamilton sold 40,164 shares of the stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $63.11, for a total transaction of $2,534,750.04. Following the transaction, the insider directly owned 171,958 shares in the company, valued at $10,852,269.38. This represents a 18.93% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Adeoye Y. Olukotun sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $67.66, for a total transaction of $676,600.00. Following the completion of the sale, the director owned 33,600 shares of the company’s stock, valued at approximately $2,273,376. The trade was a 22.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 510,836 shares of company stock worth $33,603,060 over the last ninety days. Insiders own 3.60% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ARWR. iSAM Funds UK Ltd acquired a new stake in Arrowhead Pharmaceuticals during the third quarter worth about $29,000. Empowered Funds LLC grew its holdings in shares of Arrowhead Pharmaceuticals by 6.9% during the 1st quarter. Empowered Funds LLC now owns 15,252 shares of the biotechnology company’s stock worth $194,000 after purchasing an additional 979 shares during the period. California State Teachers Retirement System increased its position in Arrowhead Pharmaceuticals by 1.3% during the 2nd quarter. California State Teachers Retirement System now owns 103,976 shares of the biotechnology company’s stock worth $1,643,000 after purchasing an additional 1,301 shares in the last quarter. Amundi raised its holdings in Arrowhead Pharmaceuticals by 11.8% in the third quarter. Amundi now owns 28,156 shares of the biotechnology company’s stock valued at $1,056,000 after buying an additional 2,962 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Arrowhead Pharmaceuticals by 9.7% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 36,775 shares of the biotechnology company’s stock valued at $1,268,000 after buying an additional 3,258 shares in the last quarter. Institutional investors and hedge funds own 62.61% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on ARWR shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, January 21st. Piper Sandler reaffirmed an “overweight” rating and set a $110.00 price objective (up previously from $100.00) on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, January 13th. Chardan Capital lifted their price objective on Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the stock a “buy” rating in a research report on Wednesday, January 7th. Bank of America upped their target price on shares of Arrowhead Pharmaceuticals from $62.00 to $81.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. Finally, Morgan Stanley lifted their price target on shares of Arrowhead Pharmaceuticals from $48.00 to $81.00 and gave the stock an “equal weight” rating in a report on Wednesday, January 7th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $81.67.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.